![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Heptares, Allergan Ink Exclusive Licensing Agreement
Heptares, Allergan Ink Exclusive Licensing Agreement
![](https://www.fdanews.com/ext/resources/test/Drug-Images3/GreenDollarSign.gif?t=1433864063&width=430)
An Allergan unit has inked an exclusive licensing agreement with Heptares Therapeutics to gain global rights to candidates targeting neurological disorders, such as Alzheimer’s disease.
Under the agreement, Heptares, a subsidiary of Sosei Group, will receive an upfront payment of $125 million, development milestones of up to $665 million and up to $2.5 billion contingent on meeting certain annual sales thresholds.
Additionally, Allergan is pouring $50 million into a joint R&D program to accelerate candidates through Phase 2 studies.
Related Events
Upcoming Events
-
21Oct